Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 17981041)

1.

Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers.

Munro TA, Duncan KK, Xu W, Wang Y, Liu-Chen LY, Carlezon WA Jr, Cohen BM, Béguin C.

Bioorg Med Chem. 2008 Feb 1;16(3):1279-86. Epub 2007 Oct 24.

2.

Synthesis and in vitro evaluation of salvinorin A analogues: effect of configuration at C(2) and substitution at C(18).

Béguin C, Richards MR, Li JG, Wang Y, Xu W, Liu-Chen LY, Carlezon WA Jr, Cohen BM.

Bioorg Med Chem Lett. 2006 Sep 1;16(17):4679-85. Epub 2006 Jun 13. Erratum in: Bioorg Med Chem Lett. 2008 Aug 1;18(15):4448.

PMID:
16777411
3.

Synthesis and in vitro pharmacological studies of C(4) modified salvinorin A analogues.

Lee DY, He M, Kondaveti L, Liu-Chen LY, Ma Z, Wang Y, Chen Y, Li JG, Beguin C, Carlezon WA Jr, Cohen B.

Bioorg Med Chem Lett. 2005 Oct 1;15(19):4169-73.

PMID:
16051487
4.

Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations.

Chavkin C, Sud S, Jin W, Stewart J, Zjawiony JK, Siebert DJ, Toth BA, Hufeisen SJ, Roth BL.

J Pharmacol Exp Ther. 2004 Mar;308(3):1197-203. Epub 2004 Jan 8.

5.

Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist.

Munro TA, Rizzacasa MA, Roth BL, Toth BA, Yan F.

J Med Chem. 2005 Jan 27;48(2):345-8.

6.

Synthesis and in vitro pharmacological studies of new C(4)-modified salvinorin A analogues.

Lee DY, He M, Liu-Chen LY, Wang Y, Li JG, Xu W, Ma Z, Carlezon WA Jr, Cohen B.

Bioorg Med Chem Lett. 2006 Nov 1;16(21):5498-502. Epub 2006 Aug 30. Erratum in: Bioorg Med Chem Lett. 2008 Mar 15;18(6):2227.

PMID:
16945525
7.

Synthesis and in vitro pharmacological studies of new C(2) modified salvinorin A analogues.

Lee DY, Karnati VV, He M, Liu-Chen LY, Kondaveti L, Ma Z, Wang Y, Chen Y, Beguin C, Carlezon WA Jr, Cohen B.

Bioorg Med Chem Lett. 2005 Aug 15;15(16):3744-7.

PMID:
15993589
8.

Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.

Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB.

Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11934-9. Epub 2002 Aug 21.

9.

Salvinorin A: a novel and highly selective kappa-opioid receptor agonist.

Yan F, Roth BL.

Life Sci. 2004 Oct 15;75(22):2615-9. Review.

PMID:
15369697
10.

Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse.

Fantegrossi WE, Kugle KM, Valdes LJ 3rd, Koreeda M, Woods JH.

Behav Pharmacol. 2005 Dec;16(8):627-33.

PMID:
16286814
11.

Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor.

Sheffler DJ, Roth BL.

Trends Pharmacol Sci. 2003 Mar;24(3):107-9. Review.

PMID:
12628350
12.

Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor.

Béguin C, Duncan KK, Munro TA, Ho DM, Xu W, Liu-Chen LY, Carlezon WA Jr, Cohen BM.

Bioorg Med Chem. 2009 Feb 1;17(3):1370-80. doi: 10.1016/j.bmc.2008.12.012. Epub 2008 Dec 14.

13.

Bioisosteric modification of salvinorin A, a potent and selective kappa-opioid receptor agonist.

Stewart DJ, Fahmy H, Roth BL, Yan F, Zjawiony JK.

Arzneimittelforschung. 2006;56(4):269-75.

PMID:
16724512
14.

Herkinorin analogues with differential beta-arrestin-2 interactions.

Tidgewell K, Groer CE, Harding WW, Lozama A, Schmidt M, Marquam A, Hiemstra J, Partilla JS, Dersch CM, Rothman RB, Bohn LM, Prisinzano TE.

J Med Chem. 2008 Apr 24;51(8):2421-31. doi: 10.1021/jm701162g. Epub 2008 Apr 2.

15.

Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.

Wang Y, Tang K, Inan S, Siebert D, Holzgrabe U, Lee DY, Huang P, Li JG, Cowan A, Liu-Chen LY.

J Pharmacol Exp Ther. 2005 Jan;312(1):220-30. Epub 2004 Sep 21.

16.

N-methylacetamide analog of salvinorin A: a highly potent and selective kappa-opioid receptor agonist with oral efficacy.

Béguin C, Potter DN, Dinieri JA, Munro TA, Richards MR, Paine TA, Berry L, Zhao Z, Roth BL, Xu W, Liu-Chen LY, Carlezon WA Jr, Cohen BM.

J Pharmacol Exp Ther. 2008 Jan;324(1):188-95. Epub 2007 Oct 19.

17.

Synthetic studies of neoclerodane diterpenes from Salvia divinorum: selective modification of the furan ring.

Harding WW, Schmidt M, Tidgewell K, Kannan P, Holden KG, Dersch CM, Rothman RB, Prisinzano TE.

Bioorg Med Chem Lett. 2006 Jun 15;16(12):3170-4. Epub 2006 Apr 18.

PMID:
16621556
18.

2-Methoxymethyl-salvinorin B is a potent kappa opioid receptor agonist with longer lasting action in vivo than salvinorin A.

Wang Y, Chen Y, Xu W, Lee DY, Ma Z, Rawls SM, Cowan A, Liu-Chen LY.

J Pharmacol Exp Ther. 2008 Mar;324(3):1073-83. Epub 2007 Dec 18.

19.

Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.

Béguin C, Potuzak J, Xu W, Liu-Chen LY, Streicher JM, Groer CE, Bohn LM, Carlezon WA Jr, Cohen BM.

Bioorg Med Chem Lett. 2012 Jan 15;22(2):1023-6. doi: 10.1016/j.bmcl.2011.11.128. Epub 2011 Dec 7.

20.

Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands.

Harding WW, Tidgewell K, Byrd N, Cobb H, Dersch CM, Butelman ER, Rothman RB, Prisinzano TE.

J Med Chem. 2005 Jul 28;48(15):4765-71.

PMID:
16033256
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk